Defence Therapeutics Inc. DTC

Company Overview

Defence Therapeutics Inc. (DTC) is a Canadian biotechnology company focused on the development of next-generation immunotherapies and vaccines, primarily targeting oncology and infectious diseases. The company operates within the biopharmaceutical and life sciences industries, with a core emphasis on improving the intracellular delivery and efficacy of therapeutic agents.

The company’s primary value proposition is its proprietary AccuTOX® and Accum™ technologies, which are designed to enhance antigen delivery into target cells, thereby strengthening immune responses. These technologies underpin DTC’s therapeutic pipeline, which includes cancer immunotherapies and vaccine platforms. Defence Therapeutics positions itself as a platform-based developer, aiming to out-license or co-develop its technologies with larger pharmaceutical partners. The company traces its origins to academic research collaborations in Canada and has evolved from a technology-focused startup into a publicly listed clinical-stage biotechnology firm.